Drabovich Andrei P, Martínez-Morillo Eduardo, Diamandis Eleftherios P
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Biochim Biophys Acta. 2015 Jun;1854(6):677-86. doi: 10.1016/j.bbapap.2014.09.006. Epub 2014 Sep 11.
Protein biomarker development is a multidisciplinary task involving basic, translational and clinical research. Integration of multidisciplinary efforts in a single pipeline is challenging, but crucial to facilitate rational discovery of protein biomarkers and alleviate existing disappointments in the field. In this review, we discuss in detail individual phases of biomarker development pipeline, such as biomarker candidate identification, verification and validation. We focus on mass spectrometry as a principal technique for protein identification and quantification, and discuss complementary -omics approaches for selection of biomarker candidates. Proteomic samples, protein-based clinical laboratory tests and limitations of biomarker development are reviewed in detail, and critical assessment of all phases of biomarker development pipeline is provided. This article is part of a Special Issue entitled: Medical Proteomics.
蛋白质生物标志物的开发是一项涉及基础、转化和临床研究的多学科任务。将多学科的努力整合到一个单一流程中具有挑战性，但对于促进蛋白质生物标志物的合理发现以及缓解该领域现有的失望状况至关重要。在本综述中，我们详细讨论了生物标志物开发流程的各个阶段，例如生物标志物候选物的识别、验证和确认。我们重点关注质谱作为蛋白质识别和定量的主要技术，并讨论用于选择生物标志物候选物的互补组学方法。详细综述了蛋白质组学样本、基于蛋白质的临床实验室检测以及生物标志物开发的局限性，并对生物标志物开发流程的所有阶段进行了批判性评估。本文是名为“医学蛋白质组学”的特刊的一部分。
